LY256548  (Synonyms: LY25684)

LY256548 (LY25648) is an orally available anti-ischemic and anti-inflammatory compound with central nervous system activity. LY256548 is an inhibitor of phospholipase A2, 5-lipoxygenase (5-LOX), and COX, and inhibits A23187 (HY-N6687)-stimulated leukotriene B4 production. LY256548 inhibits bone damage and paw swelling in the rat Freund's complete adjuvant-induced arthritis (FCA) model^[1][2].

The oral absorption of LY256548 (LY25648) in rats, dogs, and monkeys was 45%, 7%, and 12%, respectively, and the systemic bioavailability was 6%, 0.4%, and 3%, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

333.49

C₁₉H₂₇NO₂S

107889-31-6

O=C1N(CS/C1=C\C2=CC(C(C)(C)C)=C(C(C(C)(C)C)=C2)O)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ruterbories KJ, et al. Pharmacokinetics of a novel butylated hydroxytoluene-thiazolidinone CNS antiischemic agent LY256548 in rats, mice, dogs, and monkeys. Drug Metab Dispos. 1990 Sep-Oct;18(5):674-9.  [Content Brief]

  [2]. Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2.  [Content Brief]